 Sandra Luna-Fineman
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinoblastoma | 9 | 2023 | 47 | 2.920 |
Why?
| | Retinal Neoplasms | 7 | 2023 | 42 | 2.450 |
Why?
| | Hodgkin Disease | 7 | 2026 | 172 | 2.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2026 | 1969 | 1.090 |
Why?
| | Wilms Tumor | 4 | 2025 | 90 | 1.030 |
Why?
| | Neoplasms | 18 | 2024 | 2913 | 0.950 |
Why?
| | Vincristine | 5 | 2026 | 144 | 0.660 |
Why?
| | Child | 44 | 2026 | 22740 | 0.620 |
Why?
| | Eye Enucleation | 1 | 2019 | 15 | 0.610 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2021 | 101 | 0.600 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2019 | 297 | 0.580 |
Why?
| | Kidney Neoplasms | 4 | 2025 | 415 | 0.540 |
Why?
| | Guatemala | 9 | 2024 | 343 | 0.540 |
Why?
| | Developing Countries | 8 | 2025 | 317 | 0.540 |
Why?
| | Etoposide | 6 | 2026 | 168 | 0.520 |
Why?
| | Medical Oncology | 6 | 2024 | 340 | 0.510 |
Why?
| | Refusal to Treat | 1 | 2017 | 16 | 0.510 |
Why?
| | Time-to-Treatment | 1 | 2019 | 251 | 0.500 |
Why?
| | Child, Preschool | 26 | 2026 | 11868 | 0.500 |
Why?
| | Burkitt Lymphoma | 1 | 2017 | 61 | 0.490 |
Why?
| | Neoadjuvant Therapy | 1 | 2019 | 467 | 0.470 |
Why?
| | Malnutrition | 1 | 2017 | 86 | 0.460 |
Why?
| | Carboplatin | 4 | 2023 | 164 | 0.430 |
Why?
| | Antineoplastic Agents | 3 | 2023 | 2219 | 0.430 |
Why?
| | Cyclophosphamide | 4 | 2023 | 272 | 0.420 |
Why?
| | Doxorubicin | 4 | 2026 | 403 | 0.390 |
Why?
| | Survival Rate | 9 | 2025 | 2094 | 0.380 |
Why?
| | Infant | 17 | 2025 | 10091 | 0.380 |
Why?
| | Sarcoma, Ewing | 2 | 2025 | 103 | 0.350 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2017 | 688 | 0.350 |
Why?
| | Neoplasm Staging | 7 | 2019 | 1475 | 0.350 |
Why?
| | Eye Neoplasms | 1 | 2011 | 30 | 0.340 |
Why?
| | Lymphoma, Follicular | 4 | 2016 | 56 | 0.330 |
Why?
| | Adolescent | 28 | 2026 | 22577 | 0.330 |
Why?
| | Positron-Emission Tomography | 3 | 2017 | 343 | 0.300 |
Why?
| | Bone Neoplasms | 2 | 2025 | 265 | 0.300 |
Why?
| | Humans | 55 | 2026 | 145785 | 0.290 |
Why?
| | Contrast Media | 4 | 2018 | 497 | 0.270 |
Why?
| | Disease-Free Survival | 4 | 2026 | 770 | 0.270 |
Why?
| | Biomarkers, Tumor | 5 | 2025 | 1329 | 0.270 |
Why?
| | Male | 34 | 2026 | 73012 | 0.270 |
Why?
| | Practice Guidelines as Topic | 3 | 2025 | 1582 | 0.260 |
Why?
| | Female | 36 | 2026 | 79045 | 0.260 |
Why?
| | Germ-Line Mutation | 2 | 2022 | 177 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 7 | 2018 | 3916 | 0.240 |
Why?
| | Gadolinium | 2 | 2018 | 84 | 0.240 |
Why?
| | Central America | 2 | 2019 | 28 | 0.240 |
Why?
| | Hematology | 2 | 2024 | 21 | 0.220 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 391 | 0.220 |
Why?
| | Myelodysplastic Syndromes | 2 | 1999 | 165 | 0.220 |
Why?
| | Coronavirus Infections | 2 | 2020 | 384 | 0.220 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 66 | 0.220 |
Why?
| | Prognosis | 9 | 2025 | 4330 | 0.210 |
Why?
| | Clonal Evolution | 1 | 2025 | 47 | 0.210 |
Why?
| | Nephrectomy | 1 | 2025 | 163 | 0.210 |
Why?
| | Pediatrics | 5 | 2024 | 1125 | 0.200 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2015 | 161 | 0.200 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 735 | 0.190 |
Why?
| | Multimodal Imaging | 4 | 2018 | 129 | 0.190 |
Why?
| | Infant, Newborn | 8 | 2021 | 6465 | 0.190 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 361 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 1150 | 0.170 |
Why?
| | Lymphatic Irradiation | 1 | 2021 | 11 | 0.170 |
Why?
| | Libraries, Medical | 1 | 2021 | 11 | 0.170 |
Why?
| | Treatment Refusal | 2 | 2019 | 99 | 0.170 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 83 | 0.170 |
Why?
| | Disease Management | 2 | 2020 | 653 | 0.160 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 46 | 0.160 |
Why?
| | Prospective Studies | 6 | 2023 | 8078 | 0.160 |
Why?
| | Pandemics | 4 | 2022 | 1711 | 0.160 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 354 | 0.160 |
Why?
| | Herpesvirus 4, Human | 1 | 2021 | 172 | 0.150 |
Why?
| | DNA Replication | 1 | 2022 | 249 | 0.150 |
Why?
| | Ferrosoferric Oxide | 2 | 2018 | 25 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2019 | 427 | 0.150 |
Why?
| | B7-H1 Antigen | 1 | 2022 | 244 | 0.150 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 239 | 0.150 |
Why?
| | Chromosomes, Human, Pair 7 | 2 | 1999 | 17 | 0.150 |
Why?
| | Monosomy | 2 | 1999 | 10 | 0.150 |
Why?
| | DNA Repair | 1 | 2022 | 255 | 0.150 |
Why?
| | Myeloproliferative Disorders | 1 | 1999 | 21 | 0.140 |
Why?
| | Information Dissemination | 1 | 2021 | 224 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 198 | 0.140 |
Why?
| | Retrospective Studies | 9 | 2025 | 17330 | 0.140 |
Why?
| | Feasibility Studies | 1 | 2023 | 1115 | 0.140 |
Why?
| | Leukemia | 2 | 2017 | 246 | 0.140 |
Why?
| | Chromosome Aberrations | 2 | 1999 | 166 | 0.140 |
Why?
| | Fractures, Spontaneous | 1 | 2017 | 15 | 0.130 |
Why?
| | Treatment Outcome | 7 | 2026 | 11794 | 0.130 |
Why?
| | Bone Marrow Diseases | 1 | 2017 | 20 | 0.130 |
Why?
| | Nicaragua | 1 | 2017 | 7 | 0.130 |
Why?
| | Disease Progression | 3 | 2021 | 2865 | 0.130 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 1997 | 36 | 0.130 |
Why?
| | Osteonecrosis | 1 | 2017 | 23 | 0.130 |
Why?
| | Orbital Diseases | 1 | 1997 | 37 | 0.130 |
Why?
| | Delivery of Health Care | 2 | 2021 | 948 | 0.130 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 118 | 0.130 |
Why?
| | Biopsy, Needle | 1 | 1997 | 185 | 0.120 |
Why?
| | Bone Diseases | 1 | 2017 | 61 | 0.120 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 410 | 0.120 |
Why?
| | Edema | 1 | 2017 | 125 | 0.120 |
Why?
| | Young Adult | 11 | 2026 | 14254 | 0.120 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2016 | 19 | 0.120 |
Why?
| | Lymphoma | 1 | 2018 | 241 | 0.120 |
Why?
| | Risk Factors | 6 | 2021 | 10919 | 0.120 |
Why?
| | Morbidity | 1 | 2017 | 322 | 0.120 |
Why?
| | Brain Diseases | 1 | 2017 | 155 | 0.120 |
Why?
| | Income | 2 | 2023 | 203 | 0.120 |
Why?
| | Bone Marrow | 1 | 2017 | 307 | 0.110 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 280 | 0.110 |
Why?
| | Sarcoma | 1 | 2018 | 207 | 0.110 |
Why?
| | Chelating Agents | 1 | 2015 | 76 | 0.110 |
Why?
| | Aftercare | 1 | 2017 | 222 | 0.110 |
Why?
| | LIM Domain Proteins | 1 | 2015 | 20 | 0.110 |
Why?
| | Leukemia, Myeloid | 1 | 1995 | 48 | 0.110 |
Why?
| | Myeloablative Agonists | 1 | 2014 | 23 | 0.110 |
Why?
| | Chromosome Deletion | 1 | 1995 | 126 | 0.110 |
Why?
| | Indians, Central American | 1 | 2014 | 6 | 0.100 |
Why?
| | Gamma Rays | 1 | 2014 | 57 | 0.100 |
Why?
| | INDEL Mutation | 1 | 2014 | 22 | 0.100 |
Why?
| | Lymphoma, B-Cell | 2 | 1992 | 141 | 0.100 |
Why?
| | Retinoblastoma Protein | 1 | 2014 | 61 | 0.100 |
Why?
| | Receptors, Complement 3d | 1 | 2015 | 129 | 0.100 |
Why?
| | Whole Body Imaging | 1 | 2014 | 29 | 0.100 |
Why?
| | Combined Modality Therapy | 3 | 2013 | 1271 | 0.100 |
Why?
| | Central Venous Catheters | 1 | 2014 | 53 | 0.100 |
Why?
| | Heart Diseases | 1 | 2017 | 341 | 0.100 |
Why?
| | Neutropenia | 1 | 2014 | 154 | 0.100 |
Why?
| | Immunoglobulin M | 1 | 2015 | 265 | 0.100 |
Why?
| | Latin America | 3 | 2022 | 96 | 0.100 |
Why?
| | Transplantation, Autologous | 1 | 2014 | 301 | 0.100 |
Why?
| | Transplantation Conditioning | 1 | 2014 | 191 | 0.100 |
Why?
| | Point Mutation | 1 | 2014 | 241 | 0.100 |
Why?
| | Glucocorticoids | 1 | 2017 | 532 | 0.090 |
Why?
| | Radiopharmaceuticals | 1 | 2014 | 205 | 0.090 |
Why?
| | Fever | 1 | 2014 | 320 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2025 | 5428 | 0.090 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2014 | 156 | 0.090 |
Why?
| | Cerebellar Neoplasms | 1 | 2014 | 177 | 0.090 |
Why?
| | Bacterial Infections | 1 | 2014 | 247 | 0.090 |
Why?
| | Down Syndrome | 1 | 2019 | 525 | 0.090 |
Why?
| | Patient Safety | 1 | 2016 | 356 | 0.090 |
Why?
| | Medulloblastoma | 1 | 2014 | 215 | 0.090 |
Why?
| | Bacteremia | 1 | 2014 | 222 | 0.090 |
Why?
| | Time Factors | 2 | 2021 | 7134 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 426 | 0.090 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1992 | 177 | 0.090 |
Why?
| | Major Histocompatibility Complex | 1 | 1992 | 233 | 0.090 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 442 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2181 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 1 | 2015 | 625 | 0.080 |
Why?
| | Adult | 10 | 2022 | 40882 | 0.080 |
Why?
| | Crohn Disease | 1 | 2014 | 260 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2770 | 0.080 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1330 | 0.080 |
Why?
| | Incidence | 2 | 2014 | 2934 | 0.080 |
Why?
| | Macrophages | 1 | 2018 | 1507 | 0.080 |
Why?
| | Dura Mater | 1 | 2009 | 40 | 0.070 |
Why?
| | Promoter Regions, Genetic | 1 | 2014 | 1247 | 0.070 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2008 | 7 | 0.070 |
Why?
| | DNA Methylation | 1 | 2014 | 690 | 0.070 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2008 | 16 | 0.070 |
Why?
| | Meningeal Neoplasms | 1 | 2009 | 95 | 0.070 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2009 | 98 | 0.070 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 100 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 992 | 0.070 |
Why?
| | Neuroblastoma | 1 | 2009 | 174 | 0.070 |
Why?
| | Survival Analysis | 3 | 2022 | 1378 | 0.070 |
Why?
| | Idarubicin | 1 | 2007 | 5 | 0.070 |
Why?
| | Vidarabine | 1 | 2007 | 32 | 0.070 |
Why?
| | Soft Tissue Neoplasms | 1 | 2008 | 131 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 1990 | 484 | 0.060 |
Why?
| | Betacoronavirus | 2 | 2020 | 289 | 0.060 |
Why?
| | Healthcare Disparities | 1 | 2014 | 736 | 0.060 |
Why?
| | Interleukin-2 | 1 | 2007 | 440 | 0.060 |
Why?
| | Virus Shedding | 1 | 2006 | 49 | 0.060 |
Why?
| | Vinblastine | 1 | 2026 | 75 | 0.060 |
Why?
| | Mechlorethamine | 1 | 2026 | 52 | 0.060 |
Why?
| | Poliovirus | 1 | 2006 | 73 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 5925 | 0.060 |
Why?
| | Mutation | 1 | 2016 | 4090 | 0.050 |
Why?
| | Prednisone | 1 | 2026 | 226 | 0.050 |
Why?
| | Methotrexate | 1 | 2026 | 233 | 0.050 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 81 | 0.050 |
Why?
| | Societies, Medical | 2 | 2020 | 900 | 0.050 |
Why?
| | Bleomycin | 1 | 2026 | 255 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2013 | 1101 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1925 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 442 | 0.050 |
Why?
| | Suspensions | 1 | 2022 | 28 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2017 | 2000 | 0.040 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 30 | 0.040 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 31 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2021 | 3418 | 0.040 |
Why?
| | Cancer Care Facilities | 2 | 2014 | 48 | 0.040 |
Why?
| | India | 1 | 2021 | 213 | 0.040 |
Why?
| | United States | 2 | 2023 | 16126 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 2021 | 120 | 0.040 |
Why?
| | Remission Induction | 2 | 2009 | 306 | 0.040 |
Why?
| | Health Resources | 1 | 2021 | 130 | 0.040 |
Why?
| | Transcriptional Regulator ERG | 1 | 2019 | 14 | 0.040 |
Why?
| | Radiation Dosage | 1 | 2021 | 193 | 0.040 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2019 | 43 | 0.040 |
Why?
| | Fetal Hemoglobin | 1 | 1999 | 8 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 212 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1450 | 0.040 |
Why?
| | Withholding Treatment | 2 | 2011 | 80 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2019 | 194 | 0.040 |
Why?
| | Vietnam | 1 | 2018 | 27 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2399 | 0.030 |
Why?
| | Rwanda | 1 | 2018 | 35 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2020 | 536 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1777 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2021 | 1043 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 479 | 0.030 |
Why?
| | Histiocytes | 1 | 1997 | 7 | 0.030 |
Why?
| | S100 Proteins | 1 | 1997 | 35 | 0.030 |
Why?
| | Risk Assessment | 2 | 2021 | 3752 | 0.030 |
Why?
| | California | 1 | 2019 | 473 | 0.030 |
Why?
| | Haplotypes | 1 | 2019 | 500 | 0.030 |
Why?
| | Antigens, CD1 | 1 | 1997 | 60 | 0.030 |
Why?
| | Systems Integration | 1 | 2017 | 36 | 0.030 |
Why?
| | Gene Deletion | 1 | 1999 | 392 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 1997 | 200 | 0.030 |
Why?
| | Orbit | 1 | 1997 | 66 | 0.030 |
Why?
| | Registries | 2 | 2021 | 2410 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 357 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1662 | 0.030 |
Why?
| | Leukemia, Radiation-Induced | 1 | 1995 | 4 | 0.030 |
Why?
| | Genes, Neurofibromatosis 1 | 1 | 1995 | 4 | 0.030 |
Why?
| | Femur | 1 | 2017 | 254 | 0.030 |
Why?
| | Genes, ras | 1 | 1995 | 96 | 0.030 |
Why?
| | Genetic Diseases, Inborn | 1 | 1995 | 45 | 0.030 |
Why?
| | Chromosome Disorders | 1 | 1995 | 47 | 0.030 |
Why?
| | Carmustine | 1 | 2014 | 52 | 0.030 |
Why?
| | Adalimumab | 1 | 2014 | 54 | 0.030 |
Why?
| | Germinal Center | 1 | 2015 | 64 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2015 | 135 | 0.030 |
Why?
| | Tumor Cells, Cultured | 2 | 1992 | 887 | 0.030 |
Why?
| | Neoplasms, Second Primary | 1 | 1995 | 102 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 298 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1992 | 39 | 0.020 |
Why?
| | Transcription Factors | 1 | 2021 | 1736 | 0.020 |
Why?
| | CD8 Antigens | 1 | 1992 | 70 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1430 | 0.020 |
Why?
| | Risk | 1 | 1995 | 923 | 0.020 |
Why?
| | CD3 Complex | 1 | 1992 | 112 | 0.020 |
Why?
| | Interleukin-3 | 1 | 1992 | 23 | 0.020 |
Why?
| | Cancer Survivors | 1 | 2017 | 338 | 0.020 |
Why?
| | Graft vs Host Disease | 1 | 2014 | 279 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2015 | 457 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3634 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 1995 | 435 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 1139 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 478 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 334 | 0.020 |
Why?
| | Tumor Lysis Syndrome | 1 | 1990 | 10 | 0.020 |
Why?
| | Cell Communication | 1 | 1992 | 327 | 0.020 |
Why?
| | HIV Infections | 1 | 2006 | 3195 | 0.020 |
Why?
| | Treatment Failure | 1 | 2011 | 360 | 0.020 |
Why?
| | Waardenburg Syndrome | 1 | 2009 | 1 | 0.020 |
Why?
| | Microphthalmia-Associated Transcription Factor | 1 | 2009 | 14 | 0.020 |
Why?
| | Adrenalectomy | 1 | 2009 | 68 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2011 | 224 | 0.020 |
Why?
| | El Salvador | 1 | 2009 | 6 | 0.020 |
Why?
| | Honduras | 1 | 2009 | 15 | 0.020 |
Why?
| | Oncology Service, Hospital | 1 | 2009 | 15 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2015 | 872 | 0.020 |
Why?
| | Neural Crest | 1 | 2009 | 129 | 0.020 |
Why?
| | Mexico | 1 | 2009 | 233 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 2009 | 108 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 251 | 0.020 |
Why?
| | Cell Lineage | 1 | 2009 | 378 | 0.020 |
Why?
| | Immunotherapy | 1 | 1992 | 668 | 0.020 |
Why?
| | Program Development | 1 | 2009 | 368 | 0.020 |
Why?
| | Information Services | 1 | 2007 | 43 | 0.020 |
Why?
| | Italy | 1 | 2007 | 117 | 0.020 |
Why?
| | Nutrition Assessment | 1 | 2007 | 90 | 0.020 |
Why?
| | International Cooperation | 1 | 2007 | 197 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 1992 | 1505 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2668 | 0.010 |
Why?
| | Cooperative Behavior | 1 | 2007 | 463 | 0.010 |
Why?
| | Terminal Care | 1 | 2007 | 283 | 0.010 |
Why?
| | Feces | 1 | 2006 | 496 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 2009 | 853 | 0.010 |
Why?
| | Aged | 1 | 2018 | 26217 | 0.010 |
Why?
| | Middle Aged | 1 | 2018 | 36309 | 0.010 |
Why?
| | Quality of Life | 1 | 2007 | 3211 | 0.010 |
Why?
| | Receptors, Interleukin-3 | 1 | 1992 | 5 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1992 | 365 | 0.010 |
Why?
| | Cell Division | 1 | 1992 | 757 | 0.000 |
Why?
| | Recombinant Proteins | 1 | 1992 | 1368 | 0.000 |
Why?
| | Lymphocyte Activation | 1 | 1992 | 1133 | 0.000 |
Why?
|
|
Luna-Fineman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|